Advanced Glycation Endproducts in Diabetes and Diabetic Complications

Endocrinology and Metabolism Clinics of North America

Volumn 42, Issue 4, 2013, Pages 697-719

  Vlassara, Helen ^a   Striker, Gary E ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Advanced glycation endproduct; Diabetes; Insulin resistance; Metabolism

Indexed keywords

3 DEOXYGLUCOSONE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; AMINOGUANIDINE; BENFOTIAMINE; GLYOXAL, 3 DEOXYGLUCOSONE; GLYOXALASE; GLYOXALASE 1; HEMOGLOBIN A1C; LACTOYLGLUTATHIONE LYASE; METFORMIN; PYRIDOXAMINE; SIRTUIN 1; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BINDING AFFINITY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; HEMODIALYSIS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LOW DRUG DOSE; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OPTIMAL DRUG DOSE; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PERIPHERAL VASCULAR DISEASE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN MODIFICATION; REVIEW; RISK FACTOR;

ADVANCED GLYCATION ENDPRODUCT; DIABETES; INSULIN RESISTANCE; METABOLISM;

ADULT; AGING; ANIMALS; CHILD; DIABETES COMPLICATIONS; DIABETES MELLITUS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MICE; RECEPTORS, IMMUNOLOGIC;

EID: 84888091341     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2013.07.005     Document Type: Review

References (90)

1. Ward R.A., McLeish K.R. Methylglyoxal: a stimulus to neutrophil oxygen radical production in chronic renal failure?. Nephrol Dial Transplant 2004, 19(7):1702-1707.
2. Kim K.M., Kim Y.S., Jung D.H., et al. Increased glyoxalase I levels inhibit accumulation of oxidative stress and an advanced glycation end product in mouse mesangial cells cultured in high glucose. Exp Cell Res 2012, 318(2):152-159.
3. Vlassara H., Cai W., Goodman S., et al. Protection against loss of innate defenses in adulthood by low advanced glycation end products (AGE) intake: role of the antiinflammatory AGE receptor-1. JClin Endocrinol Metab 2009, 94(11):4483-4491.
4. Vlassara H., Cai W., Crandall J., et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci USA 2002, 99(24):15596-15601.
5. Koschinsky T., He C.J., Mitsuhashi T., et al. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci USA 1997, 94(12):6474-6479.
6. He C., Sabol J., Mitsuhashi T., et al. Dietary glycotoxins: inhibition of reactive products by aminoguanidine facilitates renal clearance and reduces tissue sequestration. Diabetes 1999, 48(6):1308-1315.
7. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414(6865):813-820.
8. Vlassara H., Brownlee M., Cerami A. Nonenzymatic glycosylation: role in the pathogenesis of diabetic complications. Clin Chem 1986, 32(Suppl 10):B37-B41.
9. Cai W., He J.C., Zhu L., et al. Oral glycotoxins determine the effects of calorie restriction on oxidant stress, age-related diseases, and lifespan. Am J Pathol 2008, 173(2):327-336.
10. Lind M., Garcia-Rodriguez L.A., Booth G.L., et al. Mortality trends in patients with and without diabetes in Ontario, Canada and the UK from 1996 to 2009: a population-based study. Diabetologia 2013, [Epub ahead of print].
11. Linder B.L., Fradkin J.E., Rodgers G.P. The TODAY study: an NIH perspective on its implications for research. Diabetes Care 2013, 36(6):1775-1776.
12. Vlassara H., Striker G.E. AGE restriction in diabetes mellitus: a paradigm shift. Nat Rev Endocrinol 2011, 7(9):526-539.
13. Zhao Z., Zhao C., Zhang X.H., et al. Advanced glycation end products inhibit glucose-stimulated insulin secretion through nitric oxide-dependent inhibition of cytochrome c oxidase and adenosine triphosphate synthesis. Endocrinology 2009, 150(6):2569-2576.
14. Hawa M.I., Kolb H., Schloot N., et al. Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: Action LADA 7. Diabetes Care 2013, 36(4):908-913.
15. Uribarri J., Cai W., Ramdas M., et al. Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and SIRT1. Diabetes Care 2011, 34(7):1610-1616.
16. Peppa M., Brem H., Cai W., et al. Prevention and reversal of diabetic nephropathy in db/db mice treated with alagebrium (ALT-711). Am J Nephrol 2006, 26(5):430-436.
17. Everard A., Belzer C., Geurts L., et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci USA 2013, 110(22):9066-9071.
18. Karlsson F.H., Tremaroli V., Nookaew I., et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 2013, 498(7452):99-103.
19. Cai W., He J.C., Zhu L., et al. High levels of dietary advanced glycation end products transform low-density lipoprotein into a potent redox-sensitive mitogen-activated protein kinase stimulant in diabetic patients. Circulation 2004, 110(3):285-291.
20. Staprans I., Pan X.M., Rapp J.H., et al. Oxidized cholesterol in the diet is a source of oxidized lipoproteins in human serum. JLipid Res 2003, 44(4):705-715.
21. Vistoli G., Maddis D., De Maddis D., et al. Advanced glycoxidation and lipoxidation end products (AGEs and ALEs): an overview of their mechanisms of formation. Free Radic Res 2013, 47(Suppl 1):3-27.
22. Cai W., He C., Zhu L., et al. Dietary-AGE-modified LDL is a potent redox-sensitive MAPk stimulant in diabetic patients. Circulation 2004, 110:285-291.
23. Hodgkinson C.P., Laxton R.C., Patel K., et al. Advanced glycation end-product of low density lipoprotein activates the toll-like 4 receptor pathway implications for diabetic atherosclerosis. Arterioscler Thromb Vasc Biol 2008, 28(12):2275-2281.
24. Shi H., Kokoeva M.V., Inouye K., et al. TLR4 links innate immunity and fatty acid-induced insulin resistance. JClin Invest 2006, 116(11):3015-3025.
25. Thornalley P.J. Glyoxalase I-structure, function and a critical role in the enzymatic defence against glycation. Biochem Soc Trans 2003, 31(Pt 6):1343-1348.
26. Vlassara H. The AGE-receptor in the pathogenesis of diabetic complications. Diabetes Metab Res Rev 2001, 17(6):436-443.
27. Makita Z., Bucala R., Rayfield E.J., et al. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet 1994, 343(8912):1519-1522.
28. Makita Z., Radoff S., Rayfield E.J., et al. Advanced glycosylation end products in patients with diabetic nephropathy. NEngl J Med 1991, 325(12):836-842.
29. Schmidt A.M., Yan S.D., Yan S.F., et al. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001, 108(7):949-955.
30. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414(6865):813-820.
31. Bucala R., Makita Z., Koschinsky T., et al. Lipid advanced glycosylation: pathway for lipid oxidation invivo. Proc Natl Acad Sci USA 1993, 90(14):6434-6438.
32. Baynes J.W., Thorpe S.R. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999, 48(1):1-9.
33. Fu M.X., Requena J.R., Jenkins A.J., et al. The advanced glycation end product, Nepsilon-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. JBiol Chem 1996, 271(17):9982-9986.
34. Monnier V.M., Bautista O., Kenny D., et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes 1999, 48(4):870-880.
35. Finot P.A. The absorption and metabolism of modified amino acids in processed foods. JAOAC Int 2005, 88(3):894-903.
36. Brands C.M., Alink G.M., van Boekel M.A., et al. Mutagenicity of heated sugar-casein systems: effect of the Maillard reaction. JAgric Food Chem 2000, 48:2271-2275.
37. Ahmed N., Thornalley P.J. Advanced glycation endproducts: what is their relevance to diabetic complications?. Diabetes Obes Metab 2007, 9(3):233-245.
38. Xue M., Rabbani N., Momiji H., et al. Transcriptional control of glyoxalase 1 by Nrf2 provides a stress-responsive defence against dicarbonyl glycation. Biochem J 2012, 443(1):213-222.
39. Vlassara H., Brownlee M., Cerami A. High-affinity-receptor-mediated uptake and degradation of glucose-modified proteins: a potential mechanism for the removal of senescent macromolecules. Proc Natl Acad Sci USA 1985, 82(17):5588-5592.
40. Li Y.M., Mitsuhashi T., Wojciechowicz D., et al. Molecular identity and cellular distribution of advanced glycation endproduct receptors: Relationship of p60 to OST-48 and p90 to 80K-H membrane proteins. Proc Natl Acad Sci USA 1996, 93(20):11047-11052.
41. He C.J., Koschinsky T., Buenting C., et al. Presence of diabetic complications in type 1 diabetic patients correlates with low expression of mononuclear cell AGE-receptor-1 and elevated serum AGE. Mol Med 2001, 7(3):159-168.
42. Cai W., Torreggiani M., Zhu L., et al. AGER1 regulates endothelial cell NADPH oxidase-dependent oxidant stress via PKC-delta: implications for vascular disease. Am J Physiol Cell Physiol 2009, 298(3):C624-C634.
43. Cai W., He J.C., Zhu L., et al. Advanced glycation end product (AGE) receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor. Proc Natl Acad Sci USA 2006, 103(37):13801-13806.
44. Torreggiani M., Liu H., Wu J., et al. Advanced glycation end product receptor-1 transgenic mice are resistant to inflammation, oxidative stress, and post-injury intimal hyperplasia. Am J Pathol 2009, 175(4):1722-1732.
45. Vlassara H., Uribarri J., Cai W., et al. Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease. Clin J Am Soc Nephrol 2012, 7(6):934-942.
46. Romero R., Espinoza J., Hassan S., et al. Soluble receptor for advanced glycation end products (sRAGE) and endogenous secretory RAGE (esRAGE) in amniotic fluid: modulation by infection and inflammation. J Perinat Med 2008, 36(5):388-398.
47. Yan S.F., D'Agati V., Schmidt A.M., et al. Receptor for Advanced Glycation Endproducts (RAGE): a formidable force in the pathogenesis of the cardiovascular complications of diabetes & aging. Curr Mol Med 2007, 7(8):699-710.
48. Cai W., He J.C., Zhu L., et al. Reduced oxidant stress and extended lifespan in mice exposed to a low glycotoxin diet: association with increased AGER1 expression. Am J Pathol 2007, 170(6):1893-1902.
49. Vlassara H., Li Y.M., Imani F., et al. Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol Med 1995, 1(6):634-646.
50. Gale E.A. The rise of childhood type 1 diabetes in the 20th century. Diabetes 2002, 51(12):3353-3361.
51. Beyan H., Riese H., Hawa M.I., et al. Glycotoxin and autoantibodies are additive environmentally determined predictors of type 1 diabetes: a twin and population study. Diabetes 2012, 61(5):1192-1198.
52. Cai W., Ramdas M., Zhu L., et al. Oral advanced glycation endproducts (AGEs) promote insulin resistance and diabetes by depleting the antioxidant defenses AGE receptor-1 and sirtuin 1. Proc Natl Acad Sci USA 2012, 109(39):15888-15893.
53. Liang F., Kume S., Koya D. SIRT1 and insulin resistance. Nat Rev Endocrinol 2009, 5(7):367-373.
54. Olefsky J.M., Glass C.K. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 2010, 72:219-246.
55. Krautwald M., Munch G. Advanced glycation end products as biomarkers and gerontotoxins - a basis to explore methylglyoxal-lowering agents for Alzheimer's disease?. Exp Gerontol 2010, 45(10):744-751.
56. Willette A.A., Xu G., Johnson S.C., et al. Insulin resistance, brain atrophy, and cognitive performance in late middle-aged adults. Diabetes Care 2013, 36(2):443-449.
57. Beeri M.S., Moshier E., Schmeidler J., et al. Serum concentration of an inflammatory glycotoxin, methylglyoxal, is associated with increased cognitive decline in elderly individuals. Mech Ageing Dev 2011, 132(11-12):583-587.
58. Belanger M., Yang J., Petit J.M., et al. Role of the glyoxalase system in astrocyte-mediated neuroprotection. JNeurosci 2011, 31(50):18338-18352.
59. Li W., Maloney R.E., Circu M.L., et al. Acute carbonyl stress induces occludin glycation and brain microvascular endothelial barrier dysfunction: role for glutathione-dependent metabolism of methylglyoxal. Free Radic Biol Med 2013, 54:51-61.
60. Vlassara H., Brownlee M., Cerami A. Accumulation of diabetic rat peripheral nerve myelin by macrophages increases with the presence of advanced glycosylation endproducts. JExp Med 1984, 160(1):197-207.
61. Bayer J., Rune G., Kutsche K., et al. Estrogen and the male hippocampus: genetic variation in the aromatase gene predicting serum estrogen is associated with hippocampal gray matter volume in men. Hippocampus 2013, 23(2):117-121.
62. Lepore G., Gadau S., Peruffo A., et al. Aromatase expression in cultured fetal sheep astrocytes after nitrosative/oxidative damage. Cell Tissue Res 2011, 344(3):407-413.
63. Azcoitia I., Sierra A., Veiga S., et al. Brain aromatase is neuroprotective. JNeurobiol 2001, 47(4):318-329.
64. Doublier S., Lupia E., Catanuto P., et al. Estrogens and progression of diabetic kidney damage. Curr Diabetes Rev 2011, 7(1):28-34.
65. Vlassara H., Striker L.J., Teichberg S., et al. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA 1994, 91(24):11704-11708.
66. Kato M., Dang V., Wang M., et al. TGF-beta induces acetylation of chromatin and of Ets-1 to alleviate repression of miR-192 in diabetic nephropathy. Sci Signal 2013, 6(278):ra43.
67. Richard P., Donahue R.P., Stranges S., et al. Elevated cystatin concentration and progression to pre-diabetes. Diabetes Care 2007, 30:1724-1729.
68. Zheng F., He C., Cai W., et al. Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products. Diabetes Metab Res Rev 2002, 18(3):224-237.
69. Beisswenger P.J., Howell S.K., Russell G.B., et al. Early progression of diabetic nephropathy correlates with methylglyoxal-derived advanced glycation end products. Diabetes Care 2013, [Epub ahead of print].
70. Sun J.K., Keenan H.A., Cavallerano J.D., et al. Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration: the Joslin 50-Year Medalist Study. Diabetes Care 2011, 34(4):968-974.
71. Gohda T., Niewczas M.A., Ficociello L.H., et al. Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. JAm Soc Nephrol 2012, 23(3):516-524.
72. Niewczas M.A., Gohda T., Skupien J., et al. Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. JAm Soc Nephrol 2012, 23(3):507-515.
73. Wu J., Zhang R., Torreggiani M., et al. Induction of diabetes in aged C57B6 mice results in severe nephropathy: an association with oxidative stress, endoplasmic reticulum stress, and inflammation. Am J Pathol 2010, 176(5):2163-2176.
74. Peppa M., Uribarri J., Cai W., et al. Glycoxidation and inflammation in renal failure patients. Am J Kidney Dis 2004, 43(4):690-695.
75. Vlassara H., Cai W., Chen X., et al. Managing chronic inflammation in the aging diabetic patient with CKD by diet or sevelamer carbonate: a modern paradigm shift. JGerontol A Biol Sci Med Sci 2012, 67(12):1410-1416.
76. Christiansen C.F., Johansen M.B., Christensen S., et al. Type 2 diabetes and 1-year mortality in intensive care unit patients. Eur J Clin Invest 2013, 43(3):238-247.
77. Estruch R., Ros E., Salas-Salvado J., et al. Primary prevention of cardiovascular disease with a Mediterranean diet. NEngl J Med 2013, 368(14):1279-1290.
78. Jasuja G.K., Travison T.G., Davda M., et al. Circulating estrone levels are associated prospectively with diabetes risk in men of the Framingham Heart Study. Diabetes Care 2013, 36:2591-2596.
79. Patel R., Baker S.S., Liu W., et al. Effect of dietary advanced glycation end products on mouse liver. PLoS One 2012, 7(4):e35143.
80. Miyashita T., Toyoda Y., Tsuneyama K., et al. Hepatoprotective effect of tamoxifen on steatosis and non-alcoholic steatohepatitis in mouse models. JToxicol Sci 2012, 37(5):931-942.
81. Tian G.X., Sun Y., Pang C.J., et al. Oestradiol is a protective factor for non-alcoholic fatty liver disease in healthy men. Obes Rev 2012, 13(4):381-387.
82. Florentino G., Cotrim H.P., Florentino A., et al. Hormone replacement therapy in menopausal women: risk factor or protection to nonalcoholic fatty liver disease?. Ann Hepatol 2012, 11(1):147-149.
83. Mericq V., Piccardo C., Cai W., et al. Maternally transmitted and food-derived glycotoxins: a factor preconditioning the young to diabetes?. Diabetes Care 2010, 33(10):2232-2237.
84. Sebekova K., Saavedra G., Zumpe C., et al. Plasma concentration and urinary excretion of N epsilon-(carboxymethyl)lysine in breast milk- and formula-fed infants. Ann N Y Acad Sci 2008, 1126:177-180.
85. Vasan S., Foiles P., Founds H. Therapeutic potential of breakers of advanced glycation end product-protein crosslinks. Archives of biochemistry and biophysics. Arch Biochem Biophys 2003, 419(1):89-96.
86. Voziyan P., Brown K.L., Chetyrkin S., et al. Site-specific AGE modifications in the extracellular matrix: a role for glyoxal in protein damage in diabetes. Clin Chem Lab Med 2013, 13:1-7.
87. Lewis E.J., Greene T., Spitalewiz S., et al. For the Collaborative Study Group. Pyridorin in type 2 diabetic nephropathy. J Am Soc Nephrol 2012, 23:131-136.
88. Negrean M., Stirban A., Stratmann B., et al. Effects of low- and high-advanced glycation endproduct meals on macro- and microvascular endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Clin Nutr 2007, 85(5):1236-1243.
89. Stirban A., Pop A., Tschoepe D. A randomized, double-blind, crossover, placebo-controlled trial of 6 weeks benfotiamine treatment on postprandial vascular function and variables of autonomic nerve function in Type 2 diabetes. Diabet Med 2013, [Epub ahead of print].
90. Asif M., Egan J., Vasan S., et al. An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness. Proc Natl Acad Sci USA 2000, 97(6):2809-2813.